Joseph W Kim, MD

Assistant Professor of Medicine (Medical Oncology)

Physician Biography

During his time at the NCI, Dr. Joseph Kim was involved in clinical development of novel immunotherapies, such as therapeutic cancer vaccines and immune checkpoint inhibitors, for prostate cancer and other solid tumors. He is also a recipient of several awards, including Young Investigator Award by Conquer Cancer Foundation, American Society of Clinical Oncology (ASCO). His research interests are in early drug development, particularly immunotherapies for genitourinary cancers and others, as well as in development of biomarkers to predict responses to immunotherapy and those to identify aggressive prostate cancers at high risk of recurrence and progression. He is an active member of Society of Immunotherapy of Cancer and ASCO. His clinical interest is in care of patients with prostate cancer at various stages, muscle invasive bladder cancer and those with metastatic disease.

Patient Care

Accepts new patients? Yes
Patient Type: Adult
Referrals: From patients or physicians

Patient Care Organizations

Cancer Center, Yale: Prostate and Urologic Cancers Program

Medical Oncology: Early Drug Development Program | Subset Medical Oncology Faculty

Medical Oncology

Yale Medical Group

Board Certifications

  • Internal Medicine AB of Internal Medicine (2010)

  • Medical Oncology AB of Internal Medicine (2013)

Clinical Trials

Conditions Study Title
Prostate Genitourinary Cancer Data and Specimen Repository
Bladder, Brain and Nervous System, Breast - Female, Cervix Uteri, Colon, Esophagus, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Multiple Myeloma, Non-Hodgkin's Lymphoma, Other Female Genital, Other Male Genital, Pancreas, Prostate, Rectum, Soft Tissue, Stomach, Thyroid A Phase I, Open-label, dose-escalation study of the safety and pharmacokinetics of MPDL3280A administered intravenously as a single agent to patients with locally advanced or metastatic solid tumors or hematologic malignancies
Melanoma, skin Phase I Dose Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients with Advanced Malignancies
Prostate Bayer 16544: A randomized open-label phase IIa study evaluating the efficacy and safety of radium-223 dichloride in combination with abiraterone acetate or enzalutamide in subjects with castration-resistant prostate cancer (CRPC) who have bone metastases
Prostate SWOG S1216: A PHASE III RANDOMIZED TRIAL COMPARING ANDROGEN DEPRIVATION THERAPY + TAK-700 WITH ANDROGEN DEPRIVATION THERAPY + BICALUTAMIDE IN PATIENTS WITH NEWLY DIAGNOSED METASTATIC HORMONE SENSITIVE PROSTATE CANCER
Bladder, Breast - Female, Breast - Male, Colon, Kidney, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Other Skin, Other Urinary, Pancreas, Prostate, Small Intestine, Soft Tissue, Stomach A Phase 1, Multicenter, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KTN3379 in Adult Subjects with Advanced Tumors
Bladder, Breast - Female, Colon, Lung, Melanoma, skin, Other Endocrine System, Other Respiratory and Intrathoracic Organs, Other Urinary, Ovary, Rectum, Stomach A Phase I, open-label, multiple ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications
Prostate PROSPER: A Multinational, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer
Bladder, Breast - Female, Colon, Esophagus, Kidney, Liver, Lung, Melanoma, skin, Other Female Genital, Other Skin, Ovary, Pancreas A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Subjects With Advanced Solid Tumors
ASG-22CE-13-2: A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects with Metastatic Urothelial Cancer that Express Nectin-4
Breast - Female, Kaposi's sarcoma, Lung, Melanoma, skin, Ovary, Soft Tissue A Phase 1, Open-Label Clinical Trial Evaluating the Safety, Tolerability and Immunogenicity of Intradermally Administered ID-LV305 in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1
Breast - Female, Lung, Ovary An Open-Label, Phase I, Dose-Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0575 Administered Alone and in Combination with Gemcitabine in Patients with Refractory Solid Tumors or Lymphoma
Bladder A Phase I, open-label, multicenter, dose escalation study of oral BGJ398, a pan FGF-R kinase inhibitor, in adult patients with advanced solid malignancies.
Bladder, Colon, Lip, Oral Cavity and Pharynx, Lung A Phase 1 Study of MEDI6383 (an OX40 Agonist) in Adult Subjects with Select Advanced Solid Tumors
Bladder, Breast - Female, Colon, Esophagus, Kidney, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Pancreas, Soft Tissue, Stomach A Two Part, Phase 1, Multicenter, Open-label Study of TEN-010 Given Subcutaneously Part A: A Dose-Escalation Study in Patients with Advanced Solid Tumors Part B: An Expansion Cohort in Patients with Selected Malignancies
Colon, Lung A PHASE Ib, OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF MEHD7945A AND COBIMETINIB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC CANCERS WITH MUTANT KRAS
Melanoma, skin Stand Up To Cancer Consortium - Genomics-Enabled Medicine for Melanoma (G.E.M.M.): Using Molecularly-Guided Therapy for Patients with BRAF wild-type (BRAFwt) Metastatic Melanoma
Kidney, Melanoma, skin A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0680 (AMP-514) in Subjects with Advanced Malignancies
Breast - Female, Lung, Pancreas A PHASE I, OPEN-LABEL STUDY EVALUATING THE SAFETY AND TOLERABILITY OF ESCALATING DOSES OF DLYE5953A IN PATIENTS WITH REFRACTORY SOLID TUMORS
Breast - Female, Esophagus, Eye and Orbit, Larynx, Lip, Oral Cavity and Pharynx An open-label Phase I dose-escalation study to characterize the safety, tolerability, pharmacokinetics, and maximum tolerated dose of oral BAY 1161909 in combination with weekly intravenous paclitaxel given in an intermittent dosing schedule in subjects with advanced malignancies

Edit this profile

Contact Info

Joseph W Kim, MD
Patient Care Location
Yale Cancer CenterYale-New Haven Hospital
20 York Street, Ste north Pavilion 8 & 4

New Haven, CT 06510
Mailing Address
25 York Street
PO Box 208028

New Haven, CT 06520-8028